Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0VULUJ)
| ADC Name |
TQB2101
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
TQB2101
Click to Show/Hide
|
|||||
| Organization |
Chia Tai Tianqing Pharmaceutical (CTTQ) (Originator)
|
|||||
| Drug Status |
Phase 1
|
|||||
| Antibody Name |
Anti-ROR1 antibody
|
Antibody Info | ||||
| Antigen Name |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Payload Target |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
| Disease Name | Phase 1 | Phase 2 | Phase 3 | Approved |
|---|---|---|---|---|
| Unspecific non-hodgkin lymphoma | ||||
| Colorectal cancer | ||||
| Lung cancer | ||||
| Breast cancer | ||||
| Unspecific solid tumor |